Histosonics provide the first insurance provision for the hydotion system

In the United States, major histoistics provided the first major insurance coverage of the first major system of media assumption for sale.

Michigan (BCBSM) and health plan choice Blue Care Network, Blue Care Network, initial and metastatic liver tumors create a new medical policy that covers the histosonic’s Edison system using the Edison system.

The policy coverage entered into force on February 1, 2025, provides early access to the treatment of 4.5 million residents in Michigan. A wider policy will come into force on July 1, 2025. The coverage is a victory for the treatment module that struggles to fight for a market share among more formed surgical methods.

In 2009, the University of Michigan was established by technology, HistoSonics received US Food and Drug Department (FDA) In October 2023, approval for the Edison system, The focused ultrasonic energy uses short legumes and liquefied tumors. The therapy delivered with the robot arm does not lead the same invasiveness or toxicity as traditional approaches. Edison is currently a system of HistotRiption approved by the FDA only on the market.

12 months of follow-up analysis of the HOPE4Liver study, regardless of type or origin, 90% of the local suffocal control ratio has shown the ratio. This, histosonics, says that local regional treatments in the one-year follow-up are compared to the current care standard. Includes surgical approaches, radiofrequency ablation, microwave ablation and cryoabllation, used to kill liver tumors.

The company is conducting even more clinical trials to access the system of kidneys and pancreatic cancer.

The Edison system was adopted to treat more than 1,500 patients at more than 50 US medical centers.

“The liver tumors are often the leading cause of death for serious cancer patients and is very important to enter safe, effective and non-invasive treatment options,” said histosonics’ CEO Mike Blue.

“This stage marks an important precedent and expects additional states and payers to expand hepotripia for patients with liver tumors in the United States.”

Coverage is determined against the background of the purchase discussion Financial times The main medtech says that the Histotriples expert is waiting for.

Medtronic, Ge Health and Johnson & Johnson (J & J), reportedly evaluated. Through the investment lever, J & J is a long time of histosonics in the latest cash injection, taking place in a Surrounding $ 102 million In August 2024.